New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:14 EDTRLYPRelypsa announces commercial manufacturing agreement with DSM Fine Chemicals
Relypsa announced that it has entered into a multi-year commercial manufacturing and supply agreement with DSM Fine Chemicals Austria NFG GMBH & Co. KG for the active pharmaceutical ingredient for patiromer, the company's novel polymer in development for the treatment of hyperkalemia. DSM Fine Chemicals is a business unit of the newly formed DPx Holding B.V. which also owns Patheon Pharma Services and Banner Life Sciences. In addition to DSM Fine Chemicals, the company also has an agreement with Lanxess Corporation for the supply of API. Both Lanxess and DSM Fine Chemicals have manufactured and supplied API that was used during the company's clinical development program. Relypsa expects Lanxess will be the initial sole manufacturer named in its planned New Drug Application, or NDA. The company plans to submit a NDA supplement seeking approval for DSM Fine Chemicals as an additional manufacturer upon potential U.S. approval of patiromer.
News For RLYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:26 EDTRLYPBMO Capital specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Maris, along with Dr. Kosiborod, Cardiologist, St. Luke's Mid-America Heart Institute discuss limitations of current standard of care and innovative new treatments for Hyperkalemia, including ZS Pharma’s ZS-9 and Relypsa’s Patiromer on an Analyst/Industry conference call to be held on April 27 at 11 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use